ALIMENT PHARM THER 润色咨询

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

出版年份：1987 年文章数：3252 投稿命中率： 开通期刊会员，数据随心看

出版周期：Semimonthly 自引率：9.4% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1194943, encodeId=0f9b1194943c4, content=awaiting rewiewer comments 是啥状态？送外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Sat Feb 19 00:04:12 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086368, encodeId=6709108636853, content=文章题目有没有撰写模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086367, encodeId=1517108636ef2, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586304, encodeId=275458630450, content=审稿速度:1.0<br>经验分享：刚投一篇meta分析，3小时拒稿，建议转投他们旗下的一个only online的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5259302daef50326f389537442a87163/990afa84b9e72947320d7dfe819c08d5.jpg, createdBy=48d45231791, createdName=墨墨235, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069352, encodeId=3dcc10693520d, content=请问这个杂志收casereport么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b055560087, createdName=栀子开花, createdTime=Thu Nov 11 20:03:43 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058973, encodeId=062110589e318, content=昨天刚投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9a75576637, createdName=ms3000001083069719, createdTime=Sat Oct 09 15:04:04 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602320, encodeId=aea160232011, content=三天拒稿，投的文章用的方法和他们期刊之前发过的有点像，但是做的方向不同，也被拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓凯, createdTime=Mon Jun 15 17:46:27 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563646, encodeId=d73656364621, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966037, encodeId=8b7c96603e9b, content=投稿命中率:25.0<br>经验分享：请问这个文章接受肝病综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd735088582, createdName=145cac34m09暂无昵称, createdTime=Sun May 16 16:14:06 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578567, encodeId=652f5e856777, content=这个难度大不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=)]
    2022-02-19 ms1000001073912817

    awaiting rewiewer comments 是啥状态？送外审了？

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1194943, encodeId=0f9b1194943c4, content=awaiting rewiewer comments 是啥状态？送外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Sat Feb 19 00:04:12 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086368, encodeId=6709108636853, content=文章题目有没有撰写模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086367, encodeId=1517108636ef2, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586304, encodeId=275458630450, content=审稿速度:1.0<br>经验分享：刚投一篇meta分析，3小时拒稿，建议转投他们旗下的一个only online的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5259302daef50326f389537442a87163/990afa84b9e72947320d7dfe819c08d5.jpg, createdBy=48d45231791, createdName=墨墨235, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069352, encodeId=3dcc10693520d, content=请问这个杂志收casereport么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b055560087, createdName=栀子开花, createdTime=Thu Nov 11 20:03:43 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058973, encodeId=062110589e318, content=昨天刚投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9a75576637, createdName=ms3000001083069719, createdTime=Sat Oct 09 15:04:04 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602320, encodeId=aea160232011, content=三天拒稿，投的文章用的方法和他们期刊之前发过的有点像，但是做的方向不同，也被拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓凯, createdTime=Mon Jun 15 17:46:27 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563646, encodeId=d73656364621, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966037, encodeId=8b7c96603e9b, content=投稿命中率:25.0<br>经验分享：请问这个文章接受肝病综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd735088582, createdName=145cac34m09暂无昵称, createdTime=Sun May 16 16:14:06 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578567, encodeId=652f5e856777, content=这个难度大不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=)]
    2021-12-27 MS68862005

    文章题目有没有撰写模板？

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1194943, encodeId=0f9b1194943c4, content=awaiting rewiewer comments 是啥状态？送外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Sat Feb 19 00:04:12 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086368, encodeId=6709108636853, content=文章题目有没有撰写模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086367, encodeId=1517108636ef2, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586304, encodeId=275458630450, content=审稿速度:1.0<br>经验分享：刚投一篇meta分析，3小时拒稿，建议转投他们旗下的一个only online的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5259302daef50326f389537442a87163/990afa84b9e72947320d7dfe819c08d5.jpg, createdBy=48d45231791, createdName=墨墨235, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069352, encodeId=3dcc10693520d, content=请问这个杂志收casereport么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b055560087, createdName=栀子开花, createdTime=Thu Nov 11 20:03:43 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058973, encodeId=062110589e318, content=昨天刚投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9a75576637, createdName=ms3000001083069719, createdTime=Sat Oct 09 15:04:04 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602320, encodeId=aea160232011, content=三天拒稿，投的文章用的方法和他们期刊之前发过的有点像，但是做的方向不同，也被拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓凯, createdTime=Mon Jun 15 17:46:27 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563646, encodeId=d73656364621, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966037, encodeId=8b7c96603e9b, content=投稿命中率:25.0<br>经验分享：请问这个文章接受肝病综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd735088582, createdName=145cac34m09暂无昵称, createdTime=Sun May 16 16:14:06 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578567, encodeId=652f5e856777, content=这个难度大不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=)]
    2021-12-27 MS54455111222

    撰写文章题目有没有技巧？

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1194943, encodeId=0f9b1194943c4, content=awaiting rewiewer comments 是啥状态？送外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Sat Feb 19 00:04:12 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086368, encodeId=6709108636853, content=文章题目有没有撰写模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086367, encodeId=1517108636ef2, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586304, encodeId=275458630450, content=审稿速度:1.0<br>经验分享：刚投一篇meta分析，3小时拒稿，建议转投他们旗下的一个only online的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5259302daef50326f389537442a87163/990afa84b9e72947320d7dfe819c08d5.jpg, createdBy=48d45231791, createdName=墨墨235, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069352, encodeId=3dcc10693520d, content=请问这个杂志收casereport么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b055560087, createdName=栀子开花, createdTime=Thu Nov 11 20:03:43 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058973, encodeId=062110589e318, content=昨天刚投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9a75576637, createdName=ms3000001083069719, createdTime=Sat Oct 09 15:04:04 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602320, encodeId=aea160232011, content=三天拒稿，投的文章用的方法和他们期刊之前发过的有点像，但是做的方向不同，也被拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓凯, createdTime=Mon Jun 15 17:46:27 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563646, encodeId=d73656364621, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966037, encodeId=8b7c96603e9b, content=投稿命中率:25.0<br>经验分享：请问这个文章接受肝病综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd735088582, createdName=145cac34m09暂无昵称, createdTime=Sun May 16 16:14:06 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578567, encodeId=652f5e856777, content=这个难度大不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=)]
    2020-03-10 墨墨235

    审稿速度:1.0
    经验分享：刚投一篇meta分析，3小时拒稿，建议转投他们旗下的一个only online的杂志。

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1194943, encodeId=0f9b1194943c4, content=awaiting rewiewer comments 是啥状态？送外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Sat Feb 19 00:04:12 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086368, encodeId=6709108636853, content=文章题目有没有撰写模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086367, encodeId=1517108636ef2, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586304, encodeId=275458630450, content=审稿速度:1.0<br>经验分享：刚投一篇meta分析，3小时拒稿，建议转投他们旗下的一个only online的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5259302daef50326f389537442a87163/990afa84b9e72947320d7dfe819c08d5.jpg, createdBy=48d45231791, createdName=墨墨235, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069352, encodeId=3dcc10693520d, content=请问这个杂志收casereport么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b055560087, createdName=栀子开花, createdTime=Thu Nov 11 20:03:43 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058973, encodeId=062110589e318, content=昨天刚投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9a75576637, createdName=ms3000001083069719, createdTime=Sat Oct 09 15:04:04 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602320, encodeId=aea160232011, content=三天拒稿，投的文章用的方法和他们期刊之前发过的有点像，但是做的方向不同，也被拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓凯, createdTime=Mon Jun 15 17:46:27 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563646, encodeId=d73656364621, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966037, encodeId=8b7c96603e9b, content=投稿命中率:25.0<br>经验分享：请问这个文章接受肝病综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd735088582, createdName=145cac34m09暂无昵称, createdTime=Sun May 16 16:14:06 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578567, encodeId=652f5e856777, content=这个难度大不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=)]
    2021-11-11 栀子开花

    请问这个杂志收casereport么

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1194943, encodeId=0f9b1194943c4, content=awaiting rewiewer comments 是啥状态？送外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Sat Feb 19 00:04:12 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086368, encodeId=6709108636853, content=文章题目有没有撰写模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086367, encodeId=1517108636ef2, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586304, encodeId=275458630450, content=审稿速度:1.0<br>经验分享：刚投一篇meta分析，3小时拒稿，建议转投他们旗下的一个only online的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5259302daef50326f389537442a87163/990afa84b9e72947320d7dfe819c08d5.jpg, createdBy=48d45231791, createdName=墨墨235, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069352, encodeId=3dcc10693520d, content=请问这个杂志收casereport么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b055560087, createdName=栀子开花, createdTime=Thu Nov 11 20:03:43 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058973, encodeId=062110589e318, content=昨天刚投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9a75576637, createdName=ms3000001083069719, createdTime=Sat Oct 09 15:04:04 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602320, encodeId=aea160232011, content=三天拒稿，投的文章用的方法和他们期刊之前发过的有点像，但是做的方向不同，也被拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓凯, createdTime=Mon Jun 15 17:46:27 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563646, encodeId=d73656364621, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966037, encodeId=8b7c96603e9b, content=投稿命中率:25.0<br>经验分享：请问这个文章接受肝病综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd735088582, createdName=145cac34m09暂无昵称, createdTime=Sun May 16 16:14:06 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578567, encodeId=652f5e856777, content=这个难度大不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=)]
    2021-10-09 ms3000001083069719

    昨天刚投

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1194943, encodeId=0f9b1194943c4, content=awaiting rewiewer comments 是啥状态？送外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Sat Feb 19 00:04:12 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086368, encodeId=6709108636853, content=文章题目有没有撰写模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086367, encodeId=1517108636ef2, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586304, encodeId=275458630450, content=审稿速度:1.0<br>经验分享：刚投一篇meta分析，3小时拒稿，建议转投他们旗下的一个only online的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5259302daef50326f389537442a87163/990afa84b9e72947320d7dfe819c08d5.jpg, createdBy=48d45231791, createdName=墨墨235, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069352, encodeId=3dcc10693520d, content=请问这个杂志收casereport么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b055560087, createdName=栀子开花, createdTime=Thu Nov 11 20:03:43 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058973, encodeId=062110589e318, content=昨天刚投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9a75576637, createdName=ms3000001083069719, createdTime=Sat Oct 09 15:04:04 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602320, encodeId=aea160232011, content=三天拒稿，投的文章用的方法和他们期刊之前发过的有点像，但是做的方向不同，也被拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓凯, createdTime=Mon Jun 15 17:46:27 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563646, encodeId=d73656364621, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966037, encodeId=8b7c96603e9b, content=投稿命中率:25.0<br>经验分享：请问这个文章接受肝病综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd735088582, createdName=145cac34m09暂无昵称, createdTime=Sun May 16 16:14:06 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578567, encodeId=652f5e856777, content=这个难度大不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=)]
    2020-06-15 邓凯

    三天拒稿，投的文章用的方法和他们期刊之前发过的有点像，但是做的方向不同，也被拒了。

    2

    展开2条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=1194943, encodeId=0f9b1194943c4, content=awaiting rewiewer comments 是啥状态？送外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Sat Feb 19 00:04:12 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086368, encodeId=6709108636853, content=文章题目有没有撰写模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086367, encodeId=1517108636ef2, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586304, encodeId=275458630450, content=审稿速度:1.0<br>经验分享：刚投一篇meta分析，3小时拒稿，建议转投他们旗下的一个only online的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5259302daef50326f389537442a87163/990afa84b9e72947320d7dfe819c08d5.jpg, createdBy=48d45231791, createdName=墨墨235, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069352, encodeId=3dcc10693520d, content=请问这个杂志收casereport么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b055560087, createdName=栀子开花, createdTime=Thu Nov 11 20:03:43 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058973, encodeId=062110589e318, content=昨天刚投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9a75576637, createdName=ms3000001083069719, createdTime=Sat Oct 09 15:04:04 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602320, encodeId=aea160232011, content=三天拒稿，投的文章用的方法和他们期刊之前发过的有点像，但是做的方向不同，也被拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓凯, createdTime=Mon Jun 15 17:46:27 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563646, encodeId=d73656364621, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966037, encodeId=8b7c96603e9b, content=投稿命中率:25.0<br>经验分享：请问这个文章接受肝病综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd735088582, createdName=145cac34m09暂无昵称, createdTime=Sun May 16 16:14:06 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578567, encodeId=652f5e856777, content=这个难度大不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=)]
    2018-11-26 Godmin

    请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值。

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=1194943, encodeId=0f9b1194943c4, content=awaiting rewiewer comments 是啥状态？送外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Sat Feb 19 00:04:12 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086368, encodeId=6709108636853, content=文章题目有没有撰写模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086367, encodeId=1517108636ef2, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586304, encodeId=275458630450, content=审稿速度:1.0<br>经验分享：刚投一篇meta分析，3小时拒稿，建议转投他们旗下的一个only online的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5259302daef50326f389537442a87163/990afa84b9e72947320d7dfe819c08d5.jpg, createdBy=48d45231791, createdName=墨墨235, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069352, encodeId=3dcc10693520d, content=请问这个杂志收casereport么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b055560087, createdName=栀子开花, createdTime=Thu Nov 11 20:03:43 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058973, encodeId=062110589e318, content=昨天刚投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9a75576637, createdName=ms3000001083069719, createdTime=Sat Oct 09 15:04:04 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602320, encodeId=aea160232011, content=三天拒稿，投的文章用的方法和他们期刊之前发过的有点像，但是做的方向不同，也被拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓凯, createdTime=Mon Jun 15 17:46:27 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563646, encodeId=d73656364621, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966037, encodeId=8b7c96603e9b, content=投稿命中率:25.0<br>经验分享：请问这个文章接受肝病综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd735088582, createdName=145cac34m09暂无昵称, createdTime=Sun May 16 16:14:06 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578567, encodeId=652f5e856777, content=这个难度大不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=)]
    2021-05-16 145cac34m09暂无昵称

    投稿命中率:25.0
    经验分享：请问这个文章接受肝病综述吗

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=1194943, encodeId=0f9b1194943c4, content=awaiting rewiewer comments 是啥状态？送外审了？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=75835552705, createdName=ms1000001073912817, createdTime=Sat Feb 19 00:04:12 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086368, encodeId=6709108636853, content=文章题目有没有撰写模板？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086367, encodeId=1517108636ef2, content=撰写文章题目有没有技巧？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:47 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586304, encodeId=275458630450, content=审稿速度:1.0<br>经验分享：刚投一篇meta分析，3小时拒稿，建议转投他们旗下的一个only online的杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5259302daef50326f389537442a87163/990afa84b9e72947320d7dfe819c08d5.jpg, createdBy=48d45231791, createdName=墨墨235, createdTime=Tue Mar 10 00:00:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069352, encodeId=3dcc10693520d, content=请问这个杂志收casereport么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b055560087, createdName=栀子开花, createdTime=Thu Nov 11 20:03:43 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058973, encodeId=062110589e318, content=昨天刚投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f9a75576637, createdName=ms3000001083069719, createdTime=Sat Oct 09 15:04:04 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=602320, encodeId=aea160232011, content=三天拒稿，投的文章用的方法和他们期刊之前发过的有点像，但是做的方向不同，也被拒了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=173, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/6Z8ZWzwoxxIAurMNW7AZDfIiadvWUCibIVNrexHPWrMIdOVuf8H8ccBF2ruGpZl0ibbZylPTIab8MUhG5sWaQyxhg/132, createdBy=21da5285289, createdName=邓凯, createdTime=Mon Jun 15 17:46:27 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=563646, encodeId=d73656364621, content=请问一下，这个杂志接收基础文章吗？最近做了一个分子在肠炎中的作用，临床，细胞，动物都有。并纯化了该分子蛋白证明其有临床治疗价值。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJezw9rLVo7scpm4bIb34WhXb0deaXB8picW5eMAazAJHqyt2iaj4Zw6Uecu7jrAcuWiax5TTGr2reoA/132, createdBy=02e72292772, createdName=Godmin, createdTime=Mon Nov 26 00:00:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966037, encodeId=8b7c96603e9b, content=投稿命中率:25.0<br>经验分享：请问这个文章接受肝病综述吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bd735088582, createdName=145cac34m09暂无昵称, createdTime=Sun May 16 16:14:06 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578567, encodeId=652f5e856777, content=这个难度大不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=275, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=)]
    2019-10-25 147612bem32暂无昵称

    这个难度大不

    1

    展开1条回复
共71条页码: 2/8页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分